Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT07283055

A Swiss Interprofessional Network for Reviewing Inappropriate Medication in Primary Care

A Swiss Interprofessional Network for Reviewing Inappropriate Medication in Primary Care: a Pilot Study

Status
Enrolling By Invitation
Phase
N/A
Study type
Interventional
Enrollment
250 (estimated)
Sponsor
University of Bern · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Accepted

Summary

The aim of the SINERGIC pilot study is to assess the feasibility in the Swiss context of implementing interprofessional medication reviews between GP and pharmacists, as part of a shared decision-making process with patients. The acceptability and potential effectiveness of such an intervention will also be assessed. This assessment will enable the investigators to take into account the determining factors for setting up a large-scale study to support the sustainable financing of this service in the long term.

Detailed description

The ageing population is leading to an increase in the prevalence of chronic conditions among older adults, often resulting in excessive polypharmacy. Polypharmacy, as well as the prescription of high-risk medications in this population, exposes them to more adverse effects, which can lead to falls and hospitalisation. This problem is of concern to healthcare professionals, whether they be general practitioners (GP), who have an overview of medical records, or dispensing pharmacists, who have an overview of medication. In Switzerland, these two professions still operate often in isolation from each other, but genuine collaboration is essential if we are to improve and manage polypharmacy among the elderly and limit the risks. Medication reviews are recognised as promising strategies for improving the quality of prescribing in patients with multiple medications. This pilot trial does not randomly select participants and does not include a control group. It is a hybrid study that aims both to test the effectiveness of the intervention and to prepare for its implementation. The study plans to include at least 250 patients from three groups of general practices in different settings. Participants will be aged 65 or older, take at least five chronic medications, and suffer from at least three chronic conditions. Individuals living in medical institutions will not be included. Intervention: * Step 1 (optional): Patients taking at least 10 chronic medications and experiencing adherence or side effect issues may benefit from a specialised consultation with a pharmacist. * Step 2: The pharmacist identifies any medication-related issues for each patient and discusses them directly with the general practitioner in order to agree on the necessary adjustments. * Step 3: During a medical appointment, the doctor and patient will decide together whether to implement the proposed changes. * Step 4: The pharmacist will follow up after a few days and then again after 3 months. Main objective: To assess whether this service is feasible in the context of the study. Secondary objectives: Measure whether the intervention is well accepted (questionnaires and interviews) by the patients and healthcare professionals involved. Exploratory objectives: Study the impact of the intervention on the quality of drug treatments, patients' quality of life and drug costs.

Conditions

Interventions

TypeNameDescription
OTHERMedication review* Step 1 (optional): Patients taking at least 10 chronic medications and experiencing adherence or side effect issues may benefit from a specialised consultation with a pharmacist. * Step 2: The pharmacist identifies any medication-related issues for each patient and discusses them directly with the general practitioner in order to agree on the necessary adjustments. * Step 3: During a medical appointment, the doctor and patient will decide together whether to implement the proposed changes. * Step 4: The pharmacist will follow up after a few days and then again after 3 months.

Timeline

Start date
2026-02-02
Primary completion
2026-07-30
Completion
2027-07-30
First posted
2025-12-15
Last updated
2026-02-13

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT07283055. Inclusion in this directory is not an endorsement.